Synthesis and biological evaluation of 5-benzylidenepyrimidine-2,4,6(1H,3H, 5H)-trione derivatives for the treatment of obesity-related nonalcoholic fatty liver disease

Journal of Medicinal Chemistry

Volumn 55, Issue 22, 2012, Pages 9958-9972

  Ma, Liang ^a   Xie, Caifeng ^a   Ran, Yan ^a   Liang, Xiaolin ^a   Huang, Li ^a   Pei, Heying ^a   Chen, Jinying ^a   Liu, Juan ^a   Sang, Yun ^a   Lai, Huijun ^a   Peng, Aihua ^a   Xiang, Mingli ^a   Wei, Yuquan ^a   Chen, Lijuan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [4 [(2,4,6 TRIOXOTETRAHYDROPYRIMIDIN 5 (6H)YLIDENE)METHYL]PHENOXY]PIPERIDIN 1 YL]NICOTINONITRILE; 5 [3 FLUORO 4 (1 ISONICOT INOYLPIPERIDIN 4 YLOXY)BENZYLIDENE]PYRIMIDINE 2,4,6 (1H,3H,5H)TRIONE; 5 [3 FLUORO 4 (1 NICOTINOYLPIPERIDIN 4 YLOXY)BENZYLIDENE]PYRIMIDINE 2,4,6 (1H,3H,5H)TRIONE; 5 [3 FLUORO 4 [1 [3 (1,1,2,2 TETRAFLUOROETHOXY)BENZOYL]PIPERIDIN 4 YLOXY]BENZYLIDENE]PYRIMIDINE 2,4,6 (1H,3H,5H)TRIONE; 5 [3 FLUORO 4 [1 [3 (TRIFLUOROMETHYL)BENZOYL]PIPERIDIN 4 YLOXY]BENZYLIDENE]PYRIMIDINE 2,4,6 (1H,3H,5H)TRIONE; 5 [3 FLUORO 4 [1 [3 FLUORO 4 (TRIFLUOROMETHYL)BENZOYL]PIPERIDIN 4 YLOXY]BENZYLIDENE]PYRIMIDINE 2,4,6 (1H,3H,5H)TRIONE; 5 [4 (1 ISONICOTINOYLPIPERIDIN 4 YIOXY)BENZYLIDENE]PYRIMIDINE 2,4,6 (1H,3H,5H)TRIONE; 5 [4 (1 NICOTINOYLPIPERIDIN 4 YLOXY)BENZYLIDENE]PYRIMIDINE 2,4,6 (1H,3H,5H)TRIONE; 5 [4 (1 PICOLINOYLPIPERIDIN 4 YLOXY)BENZYLIDENE]PYRIMIDINE 2,4,6 (1H,3H,5H)TRIONE; 5 [4 [1 (2 CHLOROISONICOTINOYL)PIPERIDIN 4 YLOXY]BENZYLIDENE]PYRIMIDINE 2,4,6 (1H,3H,5H)TRIONE; 5 [4 [1 (2 CHLORONICOTINOYL)PIPERIDIN 4 YLOXY] 3 FLUOROBENZYLIDENE]PYRIMIDINE 2,4,6 (1H,3H,5H)TRIONE; 5 [4 [1 (2 CHLORONICOTINOYL)PIPERIDIN 4 YLOXY]BENZYLIDENE]PYRIMIDINE 2,4,6 (1H,3H,5H)TRIONE; 5 [4 [1 (2,2 DIFLUOROBENZO[D][1,3]DIOXOLE 4 CARBONYL)PIPERIDIN 4 YLOXY] 3 FLUOROBENZYLIDENE]PYRIMIDINE 2,4,6 (1H,3H,5H)TRIONE; 5 [4 [1 (4 NITROPYRIDIN 2 YL)PIPERIDIN 4 YLOXY]BENZYLIDENE]PYRIMIDINE 2,4,6 (1H,3H,5H)TRIONE; 5 [4 [1 (5 CHLOROPICOLINOYL)PIPERIDINE 4 YLOXY]BENZYLIDENE]PYRIMIDINE 2,4,6 (1H,3H,5H)TRIONE; 5 [4 [1 (5 NITROPYRIDIN 2 YL)PIPERIDIN 4 YLOXY]BENZYLIDENE]PYRIMIDINE 2,4,6 (1H,3H,5H)TRIONE; 5 [4 [1 [3 (TRIFLUOROMETHYL)BENZOYL]PIPERIDIN 4 YLOXY]ENZYLIDENE]PYRIMIDINE 2,4,6 (1H,3H,5H)TRIONE; 5 [4 [1 [3 (TRIFLUOROMETHYL)PYRIDIN 2 YL]PIPERIDIN 4 YLOXY]BENZYLIDENE]PYRIMIDINE 2,4,6 (1H,3H,5H)TRIONE; 5 [4 [1 [3 FLUORO 4 (TRIFLUOROMETHYL)BENZOYL]PIPERIDIN 4 YLOXY]BENZYLIDENE]PYRIMIDINE 2,4,6 (1H,3H,5H)TRIONE; 5 [4 [1 [4 (DIFLUOROMETHOXY)BENZOYL]PIPERIDIN 4 YLOXY] 3 FLUOROBENZYLIDENE]PYRIMIDINE 2,4,6 (1H,3H,5H)TRIONE; 5 [4 [1 [4 (DIFLUOROMETHOXY)BENZOYL]PIPERIDIN 4 YLOXY]BENZYLIDENE]PYRIMIDINE 2,4,6(1H,3H,5H)TRIONE; 5 [4 [1 [5 (TRIFLUOROMETHYL)PYRIDIN 2 YL]PIPERIDIN 4 YLOXY]BENZYLIDENE]PYRIMIDINE 2,4,6 (1H,3H,5H)TRIONE; ADIPONECTIN; BARBITURIC ACID DERIVATIVE; CHOLESTEROL; GLUCOSE; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL COUNT; CELL SIZE; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTRAVENOUS GLUCOSE TOLERANCE TEST; LIPID DIET; LIPID STORAGE; LIVER WEIGHT; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; RAT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

3T3-L1 CELLS; ADIPOCYTES; ADIPONECTIN; ALANINE TRANSAMINASE; ANIMALS; BARBITURATES; BODY WEIGHT; CHOLESTEROL; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; FATTY LIVER; FEMALE; GLUCOSE; GLUCOSE TOLERANCE TEST; HEP G2 CELLS; HUMANS; INSULIN; INSULIN RESISTANCE; LEPTIN; MALE; MICE; MICE, INBRED C57BL; OBESITY; PIPERIDINES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; TISSUE DISTRIBUTION; TRIGLYCERIDES;

EID: 84870025259     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301164y     Document Type: Article

References (23)

1. Angulo, P. Nonalcoholic fatty liver disease N. Engl. J. Med. 2002, 346, 1221-1231
2. Polyzos, S. A.; Kountouras, J.; Zavos, C.; Tsiaousi, E. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease Diabetes Obes. Metab. 2010, 12, 365-383
3. Adams, L. A.; Angulo, P. Treatment of non-alcoholic fatty liver disease Postgrad. Med. J. 2006, 82, 315-322
4. Day, C. P. Non-alcoholic fatty liver disease: current concepts and management strategies Clin. Med. 2006, 6, 19-25
5. Hübscher, S. G. Histological assessment of non-alcoholic fatty liver disease Histopathology 2006, 49, 450-465
6. Parekh, S.; Anania, F. A. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease Gastroenterology 2007, 132, 2191-2207
7. Dixon, J. B.; Bhathal, P. S.; O'Brien, P. E. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese Gastroenterology 2001, 121, 91-100
8. Nugent, C.; Younossi, Z. M. Evaluation and management of obesity-related nonalcoholic fatty liver disease Nat. Clin. Pract. Gastroenterol. Hepatol. 2007, 4, 432-441
9. Berg, A. H.; Combs, T. P.; Scherer, P. E. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism Trends Endocrinol. Metab. 2002, 13, 84-89
10. Christos, S.; Mantzoros, M. D. The role of leptin in human obesity and disease: a review of current evidence Ann. Intern. Med. 1999, 130, 671-680
11. Nedvidkova, J.; Smitka, K.; Kopsky, V.; Hainer, V. Adiponectin, an adipocyte- derived protein Physiol. Res. 2005, 54, 133-140
12. Xu, A.; Wang, Y.; Keshaw, H.; Xu, L. Y.; Lam, K. S.; Cooper, G. J. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice J. Clin. Invest. 2003, 112, 91-100
13. Whitehead, J. P.; Richards, A. A.; Hickman, I. J.; Macdonald, G. A.; Prins, J. B. Adiponectin, a key adipokine in the metabolic syndrome Diabetes Obes. Metab. 2006, 8, 264-280
14. Hotta, K.; Funahashi, T.; Arita, Y.; Takahashi, M.; Matsuda, M.; Okamoto, Y.; Iwahashi, H.; Kuriyama, H.; Ouchi, N.; Sakai, N.; Nakajima, T.; Hasegawa, K.; Matsuzawa, Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients Arterioscler., Thromb., Vasc. Biol. 2000, 1595-1599
15. Valerio, N.; Melania, M.; Paolo, C.; Vincenzo, D.; Rita, D.; Fiorella, P.; Donatella, C.; Roberto, G.; Matilde, M. Leptin, free leptin index, insulin resistance and liver fibrosis in children with non-alcoholic fatty liver disease Eur. J. Endocrinol. 2006, 155, 735-743
16. Saltiel, A. R.; Kahn, C. R. Insulin signalling and the regulation of glucose and lipid metabolism Nature 2001, 414, 799-806
17. Ma, L.; Li, S. L; Zheng, H.; Chen, J. Y.; Lin, L.; Ye, X.; Chen, Z. Z.; Xu, Q. Y.; Chen, T.; Yang, J. C.; Qiu, N.; Wang, G. C.; Peng, A. H.; Ding, Y.; Wei, Y.-Q.; Chen, L. J. Synthesis and biological activity of novel barbituric and thiobarbituric acid derivatives against non-alcoholic fatty liver disease Eur. J. Med. Chem. 2011, 46, 2003-2010
18. Zheng, H.; Li, S. L.; Ma, L.; Cheng, L.; Deng, C. Y.; Chen, Z. Z.; Xie, C. F.; Xiang, M. L.; Jiang, W.; Chen, L. J. A novel agonist of PPAR-γ based on barbituric acid alleviates the development of non-alcoholic fatty liver disease by regulating adipocytokine expression and preventing insulin resistance Eur. J. Pharmacol. 2011, 659, 244-251
19. Ma, L.; Chen, J. Y.; Liang, X. L.; Xie, C. F.; Deng, C. Y.; Huang, L.; Peng, A. H.; Wei, Y-Q.; Chen, L. J. Synthesis and evaluation of 5-benzylidenethiazolidine- 2,4-dione derivatives for the treatment of non-alcoholic fatty liver disease Arch. Pharm. (Weinheim, Ger.) 2012, 345, 517-524
20. Vincent, P.; Jasna, K.; David, C.; Dennis, D. C.; Jeffrey, P. S.; Karen, R.; Fabienne, B. C.; Delphine, V.; Montserrat, C.; Christian, C.; Corinne, G.; Bernard, F.; Dominique, P.; Didier, L.; Denise, G.; Anthony, N.; Pierre, A. V.; Susanna, C.; Christian, R.; Thomas, R. Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase γ J. Med. Chem. 2006, 49, 3857-3871
21. Qin, N.; Li, C. B.; Jin, M. N.; Shi, L. H.; Duan, H. Q.; Niu, W. Y. Synthesis and biological activity of novel tiliroside derivants Eur. J. Med. Chem. 2011, 46, 5189-5195
22. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J. Immunol. Methods 1983, 65, 55-63
23. Sophie, P.; Peter, R. M.; Steve, S.; Veronique, G. Fluorine in medicinal chemistry Chem. Soc. Rev. 2008, 37, 320-330